References
- SinghDMaleki-YazdiMRTombsLIqbalAFahyWANayaIPrevention of clinically important deteriorations in COPD with umeclidinium/vilanterolInt J Chron Obstruct Pulmon Dis20161111413142427445468
- AnzuetoAVogelmeierCKostikasKThe effect of indacaterol/glycopyrronium versus tiotropium or salmeterol/fluticasone on the prevention of clinically important deterioration in COPDInt J Chron Obstruct Pulmon Dis2017121325133728496316
- Maleki-YazdiMRSinghDAnzuetoATombsLFahyWANayaIAssessing short-term deterioration in maintenance-naïve patients with COPD receiving umeclidinium/vilanterol and tiotropium: a pooled analysis of three randomized trialsAdv Ther201733122188219927796912
- SinghDD’UrzoADChuecosFMuñozAGarcia GilEReduction in clinically important deterioration in chronic obstructive pulmonary disease with aclidinium/formoterolRespir Res201718110628558833
- AnzuetoARKostikasKMezziKIndacaterol/glycopyrronium versus salmeterol/fluticasone in the prevention of clinically important deterioration in COPD: results from the FLAME studyRespir Res201819112129925383
- GreulichTKostikasKGagaMIndacaterol/glycopyrronium reduces the risk of clinically important deterioration after direct switch from baseline therapies in patients with moderate COPD: a post hoc analysis of the CRYSTAL studyInt J Chron Obstruct Pulmon Dis2018131229123729713156
- RabeKFMetzdorfNVobFHallmannCGronkeLTashkinDPBenefits of tiotropium versus placebo for delaying clinically significant events in patients with moderate COPD (GOLD 2)Am J Respir Crit Care Med2016193A6814
- NayaIBarnacleHBirkRClinically important deterioration in advanced COPD patients using single inhaler triple therapy: results from the FULFIL studyEur Respir J201750suppl 61PA3248
- JonesPWSt. George’s Respiratory Questionnaire: MCIDCOPD200521757917136966
- MahlerDAWitekTJThe MCID of the Transition Dyspnea Index is a total score of one unitCOPD2005219910317136969
- NayaIPTombsLMuellerovaHComptonCJonesPWLong-term outcomes following first short-term clinically important deterioration in COPDRespir Res201819122230453972
- SinghDPapiACorradiMSingle inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (trilogy): a double-blind, parallel group, randomised controlled trialThe Lancet201638810048963973
- VestboJPapiACorradiMSingle inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trialThe Lancet20173891008219191929
- PapiAVestboJFabbriLExtrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (tribute): a double-blind, parallel group, randomised controlled trialThe Lancet20183911012510761084
- DonohueJFMinimal clinically important differences in COPD lung functionCOPD20052111112417136971
- GrolimundEKutzAMarloweRJLong-term prognosis in COPD exacerbation: role of biomarkers, clinical variables and exacerbation typeCOPD201512329530525230352
- GoossensLMALeimerIMetzdorfNBeckerKRutten-van MölkenMPMHDoes the 2013 GOLD classification improve the ability to predict lung function decline, exacerbations and mortality: a post-hoc analysis of the 4-year UPLIFT trialBMC Pulm Med201414416325326750
- CelliBRThomasNEAndersonJAEffect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the torch studyAm J Respir Crit Care Med2008178433233818511702
- DonaldsonGCSeemungalTARBhowmikAWedzichaJARelationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary diseaseThorax2002571084785212324669
- HalpinDDecramerMCelliBKestenSLiuDTashkinDExacerbation frequency and course of COPDInt J Chron Obstruct Pulmon Dis2012765366123055714
- VestboJEdwardsLDScanlonPDChanges in forced expiratory volume in 1 second over time in COPDN Engl J Med2011365131184119221991892
- BafadhelMMckennaSTerrySAcute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkersAm J Respir Crit Care Med2011184666267121680942
- PittaFTroostersTProbstVSSpruitMADecramerMGosselinkRPhysical activity and hospitalization for exacerbation of COPDChest2006129353654416537849
- AlahmariADPatelARCKowlessarBSDaily activity during stability and exacerbation of chronic obstructive pulmonary diseaseBMC Pulm Med2014149824885188
- JohannesdottirSAChristiansenCFJohansenMBHospitalization with acute exacerbation of chronic obstructive pulmonary disease and associated health resource utilization: a population-based Danish cohort studyJ Med Econ201316789790623621504
- BlasiFCesanaGContiSThe clinical and economic impact of exacerbations of chronic obstructive pulmonary disease: a cohort of hospitalized patientsPLoS One201496e10122824971791
- DonohueJFJonesPWBartelsCCorrelations between FEV1 and patient-reported outcomes: a pooled analysis of 23 clinical trials in patients with chronic obstructive pulmonary diseasePulm Pharmacol Ther201849111929277690
- JonesPWDonohueJFNedelmanJPascoeSPinaultGLassenCCorrelating changes in lung function with patient outcomes in chronic obstructive pulmonary disease: a pooled analysisRespir Res20111216122206353
- Global Initiative for Chronic Obstructive Lung DiseaseGlobal Strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease Available from: https://goldcopd.org. Published 2019Accessed December 28, 2018